Annual incidence and relative risk of diabetes in people with various categories of dysglycemia: A systematic overview and meta-analysis of prospective studies

Diabetes Research and Clinical Practice

Volumn 78, Issue 3, 2007, Pages 305-312

  Gerstein, Hertzel C ^a   Santaguida, Pasqualina ^a   Raina, Parminder ^a   Morrison, Katherine M ^a   Balion, Cynthia ^b   Hunt, Dereck ^a   Yazdi, Hossein ^a   Booker, Lynda ^a  

^a HAMILTON HEALTH SCIENCES   (Canada)

^b MCMASTER UNIVERSITY   (Canada)

Author keywords

Diabetes; Dysglycemia; Impaired fasting glucose (IFG); Impaired glucose tolerance (IGT); Normoglycemia

Indexed keywords

GLUCOSE;

CLINICAL TRIAL; COHORT ANALYSIS; DIABETES MELLITUS; DIET THERAPY; DISEASE COURSE; EPIDEMIC; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; GLUCOSE TOLERANCE; HUMAN; IMPAIRED GLUCOSE TOLERANCE; INCIDENCE; LIFESTYLE MODIFICATION; META ANALYSIS; ORAL GLUCOSE TOLERANCE TEST; REVIEW; RISK FACTOR; SYSTEMATIC REVIEW;

BLOOD GLUCOSE; DIABETES MELLITUS; GLUCOSE INTOLERANCE; HUMANS; INCIDENCE; REFERENCE VALUES; RISK;

EID: 35649024167     PISSN: 01688227     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diabres.2007.05.004     Document Type: Review

References (51)

1. Secree R., Shaw J., and Zimmet P. Diabetes and impaired glucose tolerance: prevalence and projections. In: Allgot B., Gan D., King H., Lefebvre P., Mbanya J.-C., Silink M., et al. (Eds). Diabetes Atlas. 2nd ed. (2003), International Diabetes Federation, Brussels 17-71
2. Unwin N., Shaw J., Zimmet P., and Alberti K.G. Impaired glucose tolerance and impaired fasting glycaemia: the current status on definition and intervention. Diabet. Med. 19 (2002) 708-723
3. MacKay M., Scanlan A., Olsen L., Reid D., Clark M., McKim K., et al. Looking for the evidence: a systematic review of prevention strategies addressing sport and recreational injury among children and youth. J. Sci. Med. Sport 7 (2004) 58-73
4. Oremus M., Wolfson C., Perrault A., Demers L., Momoli F., and Moride Y. Interrater reliability of the modified Jadad quality scale for systematic reviews of Alzheimer's disease drug trials. Dement. Geriatr. Cogn. Disord. 12 (2001) 232-236
5. Kelsey J.L., Whittemore A.S., Evans A.S., and Thompson W.D. Methods in Observational Epidemiology. 2nd ed. (1996), Oxford University Press, New York
6. Sutton A.J., Abrams K.R., Jones D.R., Sheldon T.A., and Song F. Meta-analysis in Medical Research (2000), Wiley, Rexdale, Ontario, Canada
7. SAS Institute. Sas/STAT User's Guide vol. 8 (2001), SAS Institute Inc., Cary, NC, USA
8. Santaguida P.L., Balion C., Hunt D., Morrison K., Gerstein H., Raina P., et al. Diagnosis, prognosis, and treatment of impaired glucose tolerance and impaired fasting glucose. Evid. Rep. Technol. Assess. (Summ) (2005) 1-11
9. Ammari F., Batieha A., Jaddou P.H.H., Okashi M., and Ajlouni K. A natural history of impaired glucose tolerance in North Jordan. Pract. Diabetes Int. 15 (1998) 139-140
10. Charles M.A., Eschwege E., Thibult N., Claude J.R., Warnet J.M., Rosselin G.E., et al. The role of non-esterified fatty acids in the deterioration of glucose tolerance in Caucasian subjects: results of the Paris prospective study. Diabetologia 40 (1997) 1101-1106
11. Charles M.A., Fontbonne A., Thibult N., Warnet J.M., Rosselin G.E., and Eschwege E. Risk factors for NIDDM in white population. Paris prospective study. Diabetes 40 (1991) 796-799
12. Puavilai G., Tiewtranon V., Pensuwan S., Sriphrapradaeng A., Asawakul W., Supitak V., et al. Impaired glucose tolerance in Thai adults: status of glucose tolerance after 2-year follow up. J. Med. Assoc. Thai. 70 Suppl. 2 (1987) 68-76
13. Wat N.M., Lam T.H., Janus E.D., and Lam K.S. Central obesity predicts the worsening of glycemia in southern Chinese. Int. J. Obes. Relat. Metab. Disord. 25 (2001) 1789-1793
14. Mykkanen L., Kuusisto J., Pyorala K., and Laakso M. Cardiovascular disease risk factors as predictors of type 2 (non-insulin-dependent) diabetes mellitus in elderly subjects. Diabetologia 36 (1993) 553-559
15. Chou P., Li C.L., Wu G.S., and Tsai S.T. Progression to type 2 diabetes among high-risk groups in Kin-Chen, Kinmen. Exploring the natural history of type 2 diabetes. Diabetes Care 21 (1998) 1183-1187
16. Motala A.A., Omar M.A., and Gouws E. Transient impaired glucose tolerance in South-African Indians does not carry a risk for progression to NIDDM. Diabetes Care 20 (1997) 1101-1107
17. Motala A.A., and Omar M.A. Evaluation of WHO and NDDG criteria for impaired glucose tolerance. Diabetes Res. Clin. Pract. 23 (1994) 103-109
18. Motala A.A., Omar M.A., and Gouws E. High risk of progression to NIDDM in South-African Indians with impaired glucose tolerance. Diabetes 42 (1993) 556-563
19. Kahn S.E., Leonetti D.L., Prigeon R.L., Boyko E.J., Bergstom R.W., and Fujimoto W.Y. Proinsulin levels predict the development of non-insulin-dependent diabetes mellitus (NIDDM) in Japanese-American men. Diabet. Med. 13 (1996) S63-S66
20. Saad M.F., Knowler W.C., Pettitt D.J., Nelson R.G., Mott D.M., and Bennett P.H. The natural history of impaired glucose tolerance in the Pima Indians. N. Engl. J. Med. 319 (1988) 1500-1506
21. Saad M.F., Knowler W.C., Pettitt D.J., Nelson R.G., and Bennett P.H. Transient impaired glucose tolerance in Pima Indians: is it important?. Br. Med. J. 297 (1988) 1438-1441
22. Nelson R.G., Bennett P.H., Beck G.J., Tan M., Knowler W.C., Mitch W.E., et al. Development and progression of renal disease in Pima Indians with non-insulin-dependent diabetes mellitus. Diabetic Renal Disease Study Group. N. Engl. J. Med. 335 (1996) 1636-1642
23. Stefan N., Stumvoll M., Bogardus C., and Tataranni P.A. Elevated plasma nonesterified fatty acids are associated with deterioration of acute insulin response in IGT but not NGT. Am. J. Physiol. Endocrinol. Metab. 284 (2003) E1156-E1161
24. Little R.R., England J.D., Wiedmeyer H.M., Madsen R.W., Pettitt D.J., Knowler W.C., et al. Glycated haemoglobin predicts progression to diabetes mellitus in Pima Indians with impaired glucose tolerance. Diabetologia 37 (1994) 252-256
25. Weyer C., Tataranni P.A., Bogardus C., and Pratley R.E. Insulin resistance and insulin secretory dysfunction are independent predictors of worsening of glucose tolerance during each stage of type 2 diabetes development. Diabetes Care 24 (2001) 89-94
26. Inoue I., Takahashi K., Katayama S., Harada Y., Negishi K., Ishi J., et al. A higher proinsulin response to glucose loading predicts deteriorating fasting plasma glucose and worsening to diabetes in subjects with impaired glucose tolerance. Diabet. Med. 13 (1996) 330-336
27. Schranz A.G. Abnormal glucose tolerance in the Maltese. A population-based longitudinal study of the natural history of NIDDM and IGT in Malta. Diabetes Res. Clin. Pract. 7 (1989) 7-16
28. Norman R.J., Masters L., Milner C.R., Wang J.X., and Davies M.J. Relative risk of conversion from normoglycaemia to impaired glucose tolerance or non-insulin dependent diabetes mellitus in polycystic ovarian syndrome. Hum. Reprod. 16 (2001) 1995-1998
29. Dowse G.K., Zimmet P.Z., and Collins V.R. Insulin levels and the natural history of glucose intolerance in Nauruans. Diabetes 45 (1996) 1367-1372
30. King H., Zimmet P., Raper L.R., and Balkau B. The natural history of impaired glucose tolerance in the Micronesian population of Nauru: a 6-year follow-up study. Diabetologia 26 (1984) 39-43
31. de Vegt F., Dekker J.M., Jager A., Hienkens E., Kostense P.J., Stehouwer C.D., et al. Relation of impaired fasting and postload glucose with incident type 2 diabetes in a Dutch population: the Hoorn study. JAMA 285 (2001) 2109-2113
32. Ferrannini E., Nannipieri M., Williams K., Gonzales C., Haffner S.M., and Stern M.P. Mode of onset of type 2 diabetes from normal or impaired glucose tolerance. Diabetes 53 (2004) 160-165
33. Haffner S.M., Miettinen H., Gaskill S.P., and Stern M.P. Decreased insulin secretion and increased insulin resistance are independently related to the 7-year risk of NIDDM in Mexican-Americans. Diabetes 44 (1995) 1386-1391
34. Haffner S.M., Miettinen H., and Stern M.P. Are risk factors for conversion to NIDDM similar in high and low risk populations?. Diabetologia 40 (1997) 62-66
35. Stern M.P., Morales P.A., Valdez R.A., Monterrosa A., Haffner S.M., Mitchell B.D., et al. Predicting diabetes. Moving beyond impaired glucose tolerance. Diabetes 42 (1993) 706-714
36. Wong M.-S., Gu K., Heng D., Chew S.-K., Chew L.-S., and Tai E.S. The Singapore impaired glucose tolerance follow-up study: does the ticking clock go backward as well as forward?. Diabetes Care 26 (2003) 3024-3030
37. Li C.L., Tsai S.T., and Chou P. Relative role of insulin resistance and beta-cell dysfunction in the progression to type 2 diabetes-the Kinmen study. Diabetes Res. Clin. Pract. 59 (2003) 225-232
38. Gabir M.M., Hanson R.L., Dabelea D., Imperatore G., Roumain J., Bennett P.H., et al. The 1997 American diabetes association and 1999 World Health Organization criteria for hyperglycemia in the diagnosis and prediction of diabetes. Diabetes Care 23 (2000) 1108-1112
39. Ko G.T., Chan J.C., Tsang L.W., and Cockram C.S. Combined use of fasting plasma glucose and HbA1c predicts the progression to diabetes in Chinese subjects. Diabetes Care 23 (2000) 1770-1773
40. Ko G.T.C., Chan J.C.N., and Cockram C.S. Change of glycaemic status in Chinese subjects with impaired fasting glycaemia. Diabet. Med. 18 (2001) 745-748
41. Dinneen S.F., Maldonado III D., Leibson C.L., Klee G.G., Li H., Melton III L.J., et al. Effects of changing diagnostic criteria on the risk of developing diabetes. Diabetes Care 21 (1998) 1408-1413
42. Vermes E., Ducharme A., Bourassa M.G., Lessard M., White M., and Tardif J.C. Enalapril reduces the incidence of diabetes in patients with chronic heart failure: insight from the studies of left ventricular dysfunction (SOLVD). Circulation 107 (2003) 1291-1296
43. Keech A., Colquhoun D., Best J., Kirby A., Simes R.J., Hunt D., et al. Secondary prevention of cardiovascular events with long-term pravastatin in patients with diabetes or impaired fasting glucose: results from the LIPID trial. Diabetes Care 26 (2003) 2713-2721
44. Chiasson J.L., Josse R.G., Gomis R., Hanefeld M., Karasik A., and Laakso M. Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet 359 (2002) 2072-2077
45. Li C.L., Pan C.Y., Lu J.M., Zhu Y., Wang J.H., Deng X.X., et al. Effect of metformin on patients with impaired glucose tolerance. Diabet. Med. 16 (1999) 477-481
46. Pan X.R., Li G.W., Hu Y.W., Wang J.X., Yang W.Y., An Z.X., et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and diabetes study. Diabetes Care 20 (1997) 537-544
47. Tuomilehto J., Lindstrom J., Eriksson J.G., Valle T.T., Hamalainen H., Ilanne-Parikka P., et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N. Engl. J. Med. 344 (2001) 1343-1350
48. Knowler W.C., Barrett-Connor E., Fowler S.E., Hamman R.F., Lachin J.M., Walker E.A., et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N. Engl. J. Med. 346 (2002) 393-403
49. Wein P., Beischer N., Harris C., and Permezel M. A trial of simple versus intensified dietary modification for prevention of progression to diabetes mellitus in women with impaired glucose tolerance. Aust. N Z J Obstet. Gynaecol. 39 (1999) 162-166
50. Liao D., Asberry P.J., Shofer J.B., Callahan H., Matthys C., Boyko E.J., et al. Improvement of BMI, body composition, and body fat distribution with lifestyle modification in Japanese Americans with impaired glucose tolerance. Diabetes Care 25 (2002) 1504-1510
51. Gerstein H.C., Yusuf S., Bosch J., Pogue J., Sheridan P., Dinccag N., et al. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet 368 (2006) 1096-1105